The WACC of Xbrane Biopharma AB (XBRANE.ST) is 4.9%.
| Range | Selected | |
| Cost of equity | 4.70% - 6.50% | 5.60% |
| Tax rate | 20.60% - 20.90% | 20.75% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 4.4% - 5.5% | 4.9% |
| Category | Low | High |
| Long-term bond rate | 2.5% | 3.0% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.33 | 0.4 |
| Additional risk adjustments | 0.5% | 1.0% |
| Cost of equity | 4.70% | 6.50% |
| Tax rate | 20.60% | 20.90% |
| Debt/Equity ratio | 0.65 | 0.65 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 4.4% | 5.5% |
| Selected WACC | 4.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for XBRANE.ST:
cost_of_equity (5.60%) = risk_free_rate (2.75%) + equity_risk_premium (5.60%) * adjusted_beta (0.33) + risk_adjustments (0.75%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.